Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Acasti Pharma Inc    ACST   CA00430K4028

ACASTI PHARMA INC

(ACST)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
06/20/2019 06/21/2019 06/24/2019 06/25/2019 06/26/2019 Date
1.32(c) 1.32(c) 1.33(c) 1.42(c) 1.53(c) Last
13 894 15 464 28 800 148 150 737 262 Volume
-2.94% 0.00% +0.76% +6.77% +7.75% Change
More quotes
Financials (CAD)
Sales 2020 0,66 M
EBIT 2020 -27,2 M
Net income 2020 -22,0 M
Debt 2020 -
Yield 2020 -
Sales 2021 5,14 M
EBIT 2021 -27,2 M
Net income 2021 -11,0 M
Debt 2021 -
Yield 2021 -
P/E ratio 2020 -
P/E ratio 2021
Capi. / Sales2020 183x
Capi. / Sales2021 23,5x
Capitalization 121 M
More Financials
Company
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in... 
Sector
Pharmaceuticals
Calendar
06/26 | 01:00pmEarnings Call
More about the company
Latest news on ACASTI PHARMA INC
06/26Acasti Pharma Provides Fiscal 2019 Year-End Business Update
GL
06/24Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Coveri..
GL
06/19Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call
GL
06/04Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomi..
GL
04/24Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New ..
GL
04/15Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomizati..
GL
04/01Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading..
GL
03/26Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City..
GL
03/13Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference..
GL
02/14Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
GL
More news
Sector news : Pharmaceuticals - NEC
06:45aBAYER : lifted by new plan to tackle glyphosate lawsuits, Elliott approval
RE
06:39aBAYER : lifted by new plan to tackle glyphosate lawsuits, Elliott approval
RE
03:45aBAYER : Move to Address Glyphosate Litigation Cheers Markets
DJ
02:48aBAYER : Adds Legal Help To Resolve Liabilities
DJ
02:28aASTRAZENECA : Says Imfinzi Trial Meets Objective, Improves Patient Survival
DJ
More sector news : Pharmaceuticals - NEC
Chart ACASTI PHARMA INC
Duration : Period :
Acasti Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 5,60  CAD
Spread / Average Target 266%
Managers
NameTitle
Janelle D'Alvise President, Chief Executive Officer & Director
Roderick N. Carter Executive Chairman
Pierre Lemieux Chief Operating & Scientific Officer
Jean-Francois Boily Vice President-Finance
Jean-Marie Canan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACASTI PHARMA INC34.21%92
JOHNSON & JOHNSON11.77%376 620
ROCHE HOLDING LTD.12.78%240 245
PFIZER0.25%238 672
MERCK AND COMPANY9.33%215 086
NOVARTIS19.83%208 429